Business Description
Mercury Laboratories Ltd
ISIN : INE947G01011
Compare
Compare
Traded in other countries / regions
538964.India IPO Date
2015-02-23Description
Mercury Laboratories Ltd is an India-based pharmaceutical company. It is engaged in the manufacturing and distribution of pharmaceutical drugs, herbs, and laboratory and surgical materials. The group produces medicines and formulations in the segments of pediatrics, obstetrics, gynecology, surgeon segment, multivitamin and nutrition supplements, antibiotics, and others. The company sells its products in India and internationally, of which key revenue is derived from sales made in India.
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 1.52 | |||||
Equity-to-Asset | 0.75 | |||||
Debt-to-Equity | 0.11 | |||||
Debt-to-EBITDA | 0.55 | |||||
Interest Coverage | 16.23 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 5.94 | |||||
Beneish M-Score | -2.91 | |||||
WACC vs ROIC |
Growth Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 3.3 | |||||
3-Year EBITDA Growth Rate | -1.1 | |||||
3-Year EPS without NRI Growth Rate | 1.9 | |||||
3-Year FCF Growth Rate | -18.4 | |||||
3-Year Book Growth Rate | 11.3 |
Momentum Rank
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 84.1 | |||||
9-Day RSI | 73.58 | |||||
14-Day RSI | 67.48 | |||||
6-1 Month Momentum % | -22.26 | |||||
12-1 Month Momentum % | 7.79 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 3.08 | |||||
Quick Ratio | 2.6 | |||||
Cash Ratio | 0.65 | |||||
Days Inventory | 84.85 | |||||
Days Sales Outstanding | 112.2 | |||||
Days Payable | 78.74 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Yield % | 0.35 | |||||
Dividend Payout Ratio | 0.07 | |||||
Forward Dividend Yield % | 0.35 | |||||
5-Year Yield-on-Cost % | 0.85 | |||||
Shareholder Yield % | 0.49 |
Profitability Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 59.9 | |||||
Operating Margin % | 8.23 | |||||
Net Margin % | 7.48 | |||||
FCF Margin % | 2.59 | |||||
ROE % | 11.77 | |||||
ROA % | 8.07 | |||||
ROIC % | 9.31 | |||||
ROC (Joel Greenblatt) % | 15.37 | |||||
ROCE % | 13.75 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 20.99 | |||||
PE Ratio without NRI | 20.99 | |||||
Shiller PE Ratio | 22.59 | |||||
Price-to-Owner-Earnings | 19.44 | |||||
PEG Ratio | 2.44 | |||||
PS Ratio | 1.57 | |||||
PB Ratio | 2.33 | |||||
Price-to-Tangible-Book | 2.33 | |||||
Price-to-Free-Cash-Flow | 60.73 | |||||
Price-to-Operating-Cash-Flow | 14.43 | |||||
EV-to-EBIT | 15.85 | |||||
EV-to-EBITDA | 11.44 | |||||
EV-to-Revenue | 1.53 | |||||
EV-to-FCF | 56.86 | |||||
Price-to-Projected-FCF | 1.72 | |||||
Price-to-Peter-Lynch-Fair-Value | 3.46 | |||||
Price-to-Graham-Number | 1.48 | |||||
Price-to-Net-Current-Asset-Value | 5.22 | |||||
Earnings Yield (Greenblatt) % | 6.31 | |||||
FCF Yield % | 1.64 | |||||
Forward Rate of Return (Yacktman) % | 10.75 |